Lisata Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LSTA1, the Company’s lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults. LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics announces U.S. FDA RPDD granted to LSTA1
- Lisata Therapeutics Announces Annual Financial Results
